Recent Press Releases

Valeant Announces CFO Succession Plan And Additional Executive Appointment

Howard B. Schiller to Step Down as CFO Upon Appointment of Successor Anne Whitaker Named Executive Vice President/Company Group Chairman LAVAL, Quebec, April 29, 2015 /PRNewswire/ -- Valeant...

Teva Continues to Invigorate Injectable Portfolio with the Launch of Argatroban Injection in the United States

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVA) announces the launch of Argatroban Injection in 0.9% sodium chloride, 250 mg/250 mL for intravenous infusion only, in the...

Perrigo Rejects Latest Mylan Unsolicited Offer

Offer Remains Below Initial April 8th Proposal Based on Unaffected Mylan Stock Price Shareholders are Strongly Advised to Take No Action in Relation to the Offer Apr 29, 2015 DUBLIN, April 29,...

Amgen Announces FDA Advisory Committee Meeting To Review RepathaTM (Evolocumab) As A Treatment For High Cholesterol

THOUSAND OAKS, Calif., April 29, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug...

Mylan Raises Offer to Acquire Perrigo

Increased offer consists of $75 per share in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share POTTERS BAR, England, April 29, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today...

Hospira Reports First-Quarter 2015 Results

LAKE FOREST, Ill., April 28, 2015 /PRNewswire/ -- Hospira, Inc.

Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed

Clinical Studies Have Shown Stopping Medication Early Puts Patients at a Greater Risk of Another Heart Event and Death[1][2]

PARSIPPANY,

PFIZER REPORTS FIRST-QUARTER 2015 RESULTS

NEW YORK--()--Pfizer Inc. (NYSE:PFE) reported financial results for first-quarter 2015. The company manages its commercial operations through two distinct businesses: an Innovative...

MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval

VALENCIA, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that it will begin to manufacture a 12 unit cartridge strength of AFREZZA (insulin human) Inhalation...

Merck Announces First-Quarter 2015 Financial Results

First-Quarter 2015 Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.33 Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.35 to $3.48, Excluding Certain Items;...

Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults

- New basal insulin demonstrated glycemic control with less confirmed hypoglycemia - Paris, France - April 28, 2015 - Sanofi announced today that the European Commission has granted marketing...

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Reports First Quarter Financial Results Reports Revenues of $4.0 Billion in the First Quarter Posts First Quarter GAAP and Non-GAAP EPS of $0.71 Achieves Key Data and...

OncoGenex Regains Rights to Custirsen from Teva

BOTHELL, Wash. and VANCOUVER, British Columbia, April 27, 2015 /PRNewswire/

Mylan Board Unanimously Rejects Unsolicited Expression of Interest from Teva

Board concludes that approach grossly undervalues Mylan, includes low-quality, high-risk Teva stock, and would expose Mylan to a problematic culture and leadership with poor record of delivering s

China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer

HANGZHOU, China, April 27, 2015 /PRNewswire/ -- China Jo-Jo Drugstores, Inc.

Novartis announces Phase III study of Arzerra(R) met primary endpoint of improved progression-free survival in patients with relapsed CLL

Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most commonly...

Drug prices to treat multiple sclerosis soar, point to larger problem

PORTLAND, Ore. – A new study released today found that drugs used to treat multiple sclerosis have soared in price in the past two decades, in some cases more than 700 percent, even though...

Mylan Board Unanimously Rejects Unsolicited Expression of Interest from Teva

Board concludes that approach grossly undervalues Mylan, includes low-quality, high-risk Teva stock, and would expose Mylan to a problematic culture and leadership with poor record of delivering...

Johnson & Johnson to Host Pharmaceutical Business Review

NEW BRUNSWICK, N.J., April 20, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review

Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval

CYRAMZA Now Approved in the U.S.